CRISPR/Cas9-mediated gene deletion efficiently retards the progression of Philadelphia-positive acute lymphoblastic leukemia in a p210 BCR-ABL1T315I mutation mouse model

• Yu-Ting Tan,
• Lin Ye,
• Fei Xie,
• Jiaming Wang,
• Markus Müschen,
• Sai-Juan Chen,
• Yuet Wai Kan,
• Han Liu

Affiliations

Yu-Ting Tan

State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China;Department of Medicine, University of California San Francisco, San Francisco, CA, USA

Lin Ye

Department of Medicine, University of California San Francisco, San Francisco, CA, USA

Fei Xie

Department of Medicine, University of California San Francisco, San Francisco, CA, USA;Present address: Eureka Therapeutics, Emeryville, CA, USA

Jiaming Wang

Department of Medicine, University of California San Francisco, San Francisco, CA, USA

Markus Müschen

Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA;Department of Systems Biology, City of Hope Comprehensive Cancer Center, Monrovia, CA, USA

Sai-Juan Chen

State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Yuet Wai Kan

Department of Medicine, University of California San Francisco, San Francisco, CA, USA;Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA;Institute for Human Genetics, University of California San Francisco, San Francisco, CA, USA

Han Liu

State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China